Three cases of obinutuzumab treatment for rituximab-resistant phospholipase A 2 receptor- associated membranous nephropathy
10.3760/cma.j.cn441217-20220620-00629
- VernacularTitle:奥妥珠单抗治疗利妥昔单抗抵抗性磷脂酶A 2受体相关膜性肾病3例
- Author:
Zhenfeng ZHENG
1
;
Xi CHENG
;
Yan QI
;
Wenya SHANG
;
Li WEI
;
Dong LI
;
Junya JIA
;
Tiekun YAN
Author Information
1. 天津医科大学总医院肾内科，天津 300052
- Keywords:
Receptors, phospholipase A 2;
Glomerulonephritis, membranous;
Rituximab;
Obinutuzumab;
Remission rate
- From:
Chinese Journal of Nephrology
2023;39(4):293-297
- CountryChina
- Language:Chinese
-
Abstract:
Rituximab is currently used as a first-line therapy for phospholipase A 2 receptor-associated membranous nephropathy due to its good efficacy and safety. Although the remission rate after rituximab treatment is more than 60%, nearly 40% patients still do not respond to treatment. We used obinutuzumab to treat 3 cases of rituximab resistant PLA 2R-associated membranous nephropathy. After the first dose of 1 000 mg with or without additional dose, the amount of anti-PLA 2R antibody and urinary protein decreased significantly and the adverse reactions were mild. The results show that obinutuzumab has a certain therapeutic effect on rituximab resistant PLA 2R-associated membranous nephropathy, but the time of follow-up observation is short and can only be used as individual cases, which needs to be confirmed by a large sample and high-quality prospective cohort study.
